# Solventum Corporation (SOLV) — Stock CV

Solventum Corporation is a $15.0B healthcare company. Revenue shrank 0.9% over the last year, it keeps 17¢ of every dollar of sales as profit, and it carries $4.16B of net debt. It trades at 10.4× earnings — around the middle of its own history.

> In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments.

## Identity

- **Ticker**: SOLV
- **Sector**: Healthcare
- **Industry**: Surgical & Medical Instruments & Apparatus
- **Headquarters**: EAGAN, MN
- **Employees**: 20 000
- **Website**: https://www.solventum.com
- **Market cap**: $15.0B
- **Last price**: $87.88
- **Financial profile**: Strained

## Vitals (TTM)

- **Revenue**: $8.31B
- **Net income**: $1.43B
- **Free cash flow**: -$118M
- **Net debt**: $4.16B
- **P/E**: 10.4
- **Revenue growth (YoY)**: -0.9%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 70 |
| Growth | 18 |
| Profitability | 85 |
| Health | 42 |
| Quality | 41 |
| Moat | 61 |

## Qualifications (beginner checklist) — 6 of 10 passed

- [ ] Revenue growing — -0.9% YoY
- [x] Profitable — $1.43B TTM
- [x] Profit growing — +4.5% YoY
- [ ] Generates cash — -$118M TTM
- [ ] Debt under control — current ratio 1.02
- [x] Established company — $15.0B market cap
- [x] Not printing shares — +1.5% shares over ~5y
- [x] Proven track record — 5/5 profitable years
- [ ] Financially stable — health score 30/100
- [x] Valuation not extreme — P/E 10.4

## Experience (career milestones)

- **FY2025** — Best year on record: $1.56B net income
- **Feb 25, 2025** — It was announced that Thermo Fisher Scientific would acquire the company's Purification &…
- **Apr 1, 2024** — Solventum Corporation is an American health care company that was spun off from 3M on April 1, 2024
- **FY2023** — Became debt-free: cash now exceeds total debt
- **Nov 16, 2023** — 3M unveiled that the new company would be called Solventum, a portmanteau of the words…
- **FY2021** — Profitable every year on record: 5 consecutive profitable years in our data
- **FY2021** — Revenue already above $1B: $8.17B in first reported year

## Strengths

- High gross margin (54.8%)
- Interest covered 6.1× by operating earnings
- High returns on invested capital (ROIC 16.9%)

## Watch-outs

- Revenue shrinking 0.9% year over year
- Negative free cash flow (-$118.0M)

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $8.17B | $1.46B | $1.93B |
| FY2022 | $8.13B | $1.34B | $1.43B |
| FY2023 | $8.20B | $1.35B | $1.63B |
| FY2024 | $8.25B | $479M | $805M |
| FY2025 | $8.32B | $1.56B | -$10.0M |

---

Source: https://stockcv.com/SOLV — derived from company filings; may be delayed or incomplete. Information, not investment advice.